- Home
- NCL vs QTTB Comparison
NCL vs QTTB Comparison
Compare NCL & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCL
- QTTB
- Stock Information
- Founded
- NCL 2013
- QTTB 2015
- Country
- NCL United States
- QTTB United States
- Employees
- NCL N/A
- QTTB N/A
- Industry
- NCL
- QTTB Biotechnology: Pharmaceutical Preparations
- Sector
- NCL
- QTTB Health Care
- Exchange
- NCL Nasdaq
- QTTB Nasdaq
- Market Cap
- NCL 21.7M
- QTTB 19.0M
- IPO Year
- NCL 2023
- QTTB N/A
- Fundamental
- Price
- NCL $0.16
- QTTB $1.50
- Analyst Decision
- NCL
- QTTB Hold
- Analyst Count
- NCL 0
- QTTB 8
- Target Price
- NCL N/A
- QTTB $24.00
- AVG Volume (30 Days)
- NCL 17.1M
- QTTB 142.2K
- Earning Date
- NCL 08-13-2025
- QTTB 08-07-2025
- Dividend Yield
- NCL N/A
- QTTB N/A
- EPS Growth
- NCL N/A
- QTTB N/A
- EPS
- NCL N/A
- QTTB N/A
- Revenue
- NCL $15,576,857.00
- QTTB N/A
- Revenue This Year
- NCL N/A
- QTTB N/A
- Revenue Next Year
- NCL N/A
- QTTB N/A
- P/E Ratio
- NCL N/A
- QTTB N/A
- Revenue Growth
- NCL 47.13
- QTTB N/A
- 52 Week Low
- NCL $0.15
- QTTB $1.38
- 52 Week High
- NCL $1.52
- QTTB $53.79
- Technical
- Relative Strength Index (RSI)
- NCL 36.24
- QTTB 40.47
- Support Level
- NCL $0.16
- QTTB $1.47
- Resistance Level
- NCL $0.19
- QTTB $1.65
- Average True Range (ATR)
- NCL 0.03
- QTTB 0.12
- MACD
- NCL -0.03
- QTTB -0.02
- Stochastic Oscillator
- NCL 6.82
- QTTB 15.69
About NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe.
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.